Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed · Phase 2

Conditions studied: Leukemia, Acute Lymphoblastic Leukemia

In brief

The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.

Key facts

Study ID

NCT00671658

Run by

M.D. Anderson Cancer Center

People needed

220

Starts

2002-11-01

Expected to finish

2013-07-01

Last updated by the study team

2020-12-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed, previously untreated Acute Lymphoblastic Leukemia (ALL) or lymphoblastic lymphoma, or having achieved Complete Remission (CR) with one course of induction chemotherapy.
• Failure to one induction course of chemotherapy are eligible, but these patients will be analyzed separately.
• All ages are eligible.
• Zubrod performance less than or equal to 3
• Adequate liver function (bilirubin </= 3.0 mg/dl unless considered due to tumor) and renal function (creatinine </= 3.0 mg/dl, unless considered due to tumor).
• Adequate cardiac function as assessed by history and physical examination.
• No active co-existing malignancy with life expectancy less than 12 months due to that malignancy.

You may not qualify if…

• N/A

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.